Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.